Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat. CAMBRIDGE, MA / ACC ...
Moderna Inc. was hit with a new lawsuit alleging the vaccine maker’s Spikevax Covid-19 shots infringe 10 CureVac SE patents ...
By Blake Brittain April 24 (Reuters) - German biotech company CureVac sued Moderna in Delaware federal court on Friday, ...
COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's ...
The world’s first combination seasonal influenza and COVID-19 vaccine, Moderna’s mCombriax, has received marketing ...
Zacks Investment Research on MSN
Moderna (MRNA) may report negative earnings: Know the trend ahead of next week's release
The market expects Moderna (MRNA) to deliver a year-over-year increase in earnings on higher revenues when it reports results ...
A new effort to prepare for future avian influenza outbreaks is moving forward despite a major funding setback.
April 21 (Reuters) - Moderna said on Tuesday the European Commission had approved its combination vaccine for the prevention ...
Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...
This week, the European Commission authorized Moderna to market the vaccine, mRNA-1083 or mCOMBRIAX, making it the world’s ...
After more than half a century of mandatory vaccination, the U.S. military will no longer require all American troops to get ...
A phase 3 study of Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate has been initiated. Read more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results